Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study

Hao-Ting Chang, Mei-Ling Chiu, Tao-Yuean Wang, Tzu-Chien Chen, Chih-Long Chang, Tsung-Hsien Su, Kuo-Gong Wang, Kung-Liahng Wang, Yuh-Cheng Yang and Jen-Ruei Chen
Additional contact information
Hao-Ting Chang: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Mei-Ling Chiu: Department of Pathology, MacKay Memorial Hospital, New Taipei City 25160, Taiwan
Tao-Yuean Wang: Department of Pathology, MacKay Memorial Hospital, New Taipei City 25160, Taiwan
Tzu-Chien Chen: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Chih-Long Chang: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Tsung-Hsien Su: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Hsinchu Branch, Hsinchu 30071, Taiwan
Kuo-Gong Wang: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Kung-Liahng Wang: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taitung Branch, Taitung 95054, Taiwan
Yuh-Cheng Yang: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan
Jen-Ruei Chen: Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan

IJERPH, 2020, vol. 17, issue 2, 1-10

Abstract: Ovarian clear cell carcinoma (OCCC) is the second common histology of epithelial ovarian cancer in Taiwan. Stage IC is common, especially during minimally invasive surgery. Adjuvant chemotherapy in stage IC OCCC is unavoidable, and paclitaxel-based chemotherapy in Taiwan is self-paid. However, surgical spillage from minimally invasive surgery as a cause of unfavorable prognosis is still uncertain. The information of patients with stage IC OCCC, corresponding to a period of January 1995 to December 2016, was retrospectively collected following a chart and pathology review. Data regarding surgical methods, cytology status, regimens of adjuvant chemotherapy, survivorship, progression-free survival (PFS), and overall survival (OS) period were analyzed. In total, 88 patients were analyzed, and 64 and 24 patients were treated with paclitaxel- and nonpaclitaxel-based chemotherapy, respectively. Recurrence was identical between the two groups: PFS (47.5 ± 41.36 versus 54.0 ± 53.9 months, p = 0.157) and OS (53.5 ± 38.14 versus 79.0 ± 49.42 months, p = 0.070). Of the 88 patients, 12 had undergone laparoscopy for histological confirmation before complete open staging surgery; however, their PFS (49.5 ± 46.84 versus 49.0 ± 35.55 months, p = 0.719) and OS (56.5 ± 43.4 versus 51.0 ± 32.77 months, p = 0.600) were still comparable. Cytology results were only available for 51 patients, and positive washing cytology results seemed to worsen PFS ( p = 0.026) but not OS ( p = 0.446). In conclusion, adjuvant nonpaclitaxel chemotherapy and laparoscopic tumor spillage before the staging operation did not worsen the outcome in stage IC OCCC. Positive washing cytology has a negative effect on PFS but not on OS.

Keywords: chemotherapy; clear cell carcinoma; cytology; laparoscopy; ovarian cancer; paclitaxel (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/2/491/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/2/491/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:2:p:491-:d:308055

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().